NEXGEL, INC.: management transactions · United States · SEC (Form 4)

About NEXGEL, INC.

NEXGEL, Inc. (NASDAQ: NXGL, NXGLW) is a U.S.-listed small-cap company focused on ultra-gentle, high-water-content hydrogel products for healthcare, consumer, and OTC applications. The company is headquartered in Langhorne, Pennsylvania, United States, at 2150 Cabot Boulevard West, Suite B. Its listing on the NASDAQ Capital Market places it in a micro-/small-cap profile that can offer operating leverage and product optionality, but also comes with the typical liquidity, financing, and execution risks of an emerging specialty healthcare company. ([ir.nexgel.com](https://ir.nexgel.com/?utm_source=openai)) NEXGEL’s business is built around electron-beam cross-linked hydrogel technology that it says it has developed and manufactured for more than two decades. The platform is designed to produce skin-friendly patches and gel formats that can be manufactured with or without active ingredients, supporting applications across OTC consumer products, wound care, cosmetics, and certain medical-use cases. The company’s commercialization efforts began to take shape in 2020, when it launched proprietary consumer products and created NEXGEL Rx to explore hydrogel-based drug and cell delivery applications. ([ir.nexgel.com](https://ir.nexgel.com/?utm_source=openai)) From a reporting standpoint, the company describes four distinct lines of business: contract manufacturing, custom & white label, consumer branded products, and medical devices/other. That mix is important because it shows NEXGEL is not just a branded-products story; it also monetizes manufacturing know-how and formulation capabilities through third-party and private-label work. Key branded offerings mentioned in company materials include Fever Cool, Hexagel, ClearComfort, and Nip Defense, along with newer initiatives such as TURFGUARD. The company positions itself as a provider of flexible hydrogel solutions for OTC medications, wound care, and cosmetics, with an emphasis on comfort and low skin irritation. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1468929/000149315226014377/form10-k.htm?utm_source=openai)) Competitively, NEXGEL occupies a niche within the broader health, beauty, and medtech ecosystem. Its edge lies in the formulation of high-water-content patches and gels that can be tailored for sensitive-skin use and differentiated delivery characteristics. At the same time, it faces competition from larger medical-device, consumer-health, and personal-care companies with broader distribution and greater scale. Management has attempted to strengthen the operating model by partnering on manufacturing and packaging capacity; notably, the 2023 joint venture with C.G. Laboratories was intended to improve capacity, margins, and supply-chain efficiency. ([ir.nexgel.com](https://ir.nexgel.com/news-events/press-releases/detail/47/nexgel-acquires-50-interest-in-newly-formed-joint-venture?utm_source=openai)) Geographically, the company remains primarily U.S.-based, with operations centered in Pennsylvania and commercial efforts expanded through independent sales representation. Recent corporate developments include a February 2026 financing tied to a potential acquisition, the filing of the 2025 annual report, and multiple Form 4 insider transaction filings in 2025, which underline the active monitoring of insider ownership changes on this NASDAQ name. For international equity investors, NEXGEL offers a healthcare-oriented niche growth narrative with potential upside from product expansion and manufacturing scale, but it should be viewed as a speculative small-cap with meaningful balance-sheet and execution risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1468929/000149315226006124/ex99-1.htm?utm_source=openai))